Nikola Trbovic, PhD

Nikola joined SV Health Investors in 2022 and is a Managing Partner in the Biotech team. Nikola currently serves as a Director on the Boards of Artios, Catamaran Bio, Prilenia, Sitryx and TRexBio. Previously, Nikola was a Partner at Pfizer Ventures, Pfizer’s corporate venture capital group. There he was responsible for investments in emerging companies developing transformative medicines spanning all therapeutic areas and modalities aligned with the future directions of Pfizer. In prior roles at Pfizer, Nikola held responsibilities for R&D technology investments, R&D strategy and early clinical portfolio management within the R&D organization. Nikola joined Pfizer from McKinsey & Co., where he served as an Associate Principal and senior member of the Pharmaceuticals Practice, advising top pharmaceutical, biotech, and healthcare companies on a range of strategy, corporate finance and commercial topics across geographies and therapeutic areas. 

Nikola received his PhD in Biochemistry and Molecular Biophysics from Columbia University, and holds a Diplom in Biochemistry from Goethe University Frankfurt.